Martha Wafer, MD
Family Medicine · Bossier City, LANPI 1619179421
Payments from drug & device makers
Across 485 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$859
- AbbVie$838
- GSK$695
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$595
- Novo Nordisk$448
- Astellas Pharma US Inc$433
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,07298%
- Education$1362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $859 |
| AbbVie(2 entities) | 67 | $838 |
| GSK | 49 | $695 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 51 | $595 |
| Novo Nordisk | 37 | $448 |
| Astellas Pharma US Inc | 20 | $433 |
| Sumitomo Pharma America, Inc. | 28 | $430 |
| Teva Pharmaceuticals USA, Inc. | 44 | $374 |
| Pfizer | 23 | $350 |
| Amgen | 15 | $344 |
| Indivior Inc. | 9 | $214 |
| Amarin Pharma, Inc. | 6 | $208 |
| Sanofi-aventis U.S. LLC | 9 | $200 |
| Sunovion Pharmaceuticals Inc. | 15 | $158 |
| Lilly USA, LLC | 9 | $153 |
| Merck | 7 | $102 |
| Vanda Pharmaceuticals Inc. | 4 | $90 |
| Ardelyx, Inc. | 4 | $86 |
| Boehringer Ingelheim | 5 | $75 |
| Bayer | 4 | $69 |
| Ironwood Pharmaceuticals, Inc | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $39 |
| Braeburn Inc. | 2 | $38 |
| Exact Sciences | 2 | $37 |
| Shield Therapeutics Inc | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $29 |
| Dexcom, Inc. | 1 | $27 |
| Novartis | 2 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Alkermes, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,209 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 20 | $521,840 |
| Invega SustennaPaliperidone Palmitate | 42 | $136,857 |
| OzempicSemaglutide | 116 | $127,590 |
| LinzessLinaclotide | 119 | $111,566 |
| TrulicityDulaglutide | 50 | $88,806 |
| JardianceEmpagliflozin | 72 | $82,183 |
| MounjaroTirzepatide | 59 | $78,792 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $50,601 |
| FarxigaDapagliflozin Propanediol | 49 | $45,368 |
| EliquisApixaban | 45 | $41,817 |
| MyrbetriqMirabegron | 46 | $37,784 |
| RybelsusSemaglutide | 33 | $35,979 |
| TradjentaLinagliptin | 28 | $28,897 |
| JanuviaSitagliptin Phosphate | 22 | $25,143 |
| Risperdal ConstaRisperidone Microspheres | 16 | $20,198 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris, Farxiga, Symbicort | $859 | $576,96288 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Xarelto | $29 | $170,71469 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $153 | $167,598109 claims |
| Novo NordiskOzempic, Rybelsus | $448 | $163,568149 claims |
| AbbVieLinzess, Qulipta | $838 | $125,924131 claims |
| Boehringer IngelheimJardiance, Tradjenta | $75 | $111,080100 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $695 | $74,97198 claims |
| PfizerEliquis | $350 | $41,81745 claims |
| Astellas Pharma US IncMyrbetriq | $433 | $37,78446 claims |
| MerckJanuvia | $102 | $25,14322 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $430 | $18,01229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Bossier City
- Clint WilsonBossier City$208K
- Jason MilliganBossier City$15K
- Michael AngeloBossier City$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.